200 related articles for article (PubMed ID: 26408726)
1. Carbon-ion Radiotherapy for Prostate Cancer: Analysis of Morbidities and Change in Health-related Quality of Life.
Ishikawa H; Katoh H; Kaminuma T; Kawamura H; Ito K; Matsui H; Hirato J; Shimizu N; Takezawa Y; Tsuji H; Suzuki K; Ohno T; Nakano T;
Anticancer Res; 2015 Oct; 35(10):5559-66. PubMed ID: 26408726
[TBL] [Abstract][Full Text] [Related]
2. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions.
Okada T; Tsuji H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Tsujii H;
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):968-72. PubMed ID: 22898380
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
4. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study.
Ishikawa H; Tsuji H; Kamada T; Yanagi T; Mizoe JE; Kanai T; Morita S; Wakatsuki M; Shimazaki J; Tsujii H;
Radiother Oncol; 2006 Oct; 81(1):57-64. PubMed ID: 16971008
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer.
Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Tsujii H
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1084-91. PubMed ID: 16979840
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
8. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.
Choo R; Pearse M; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):989-95. PubMed ID: 18436391
[TBL] [Abstract][Full Text] [Related]
9. Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer - acute toxicity of 12C for PC.
Nikoghosyan AV; Schulz-Ertner D; Herfarth K; Didinger B; Münter MW; Jensen AD; Jäkel O; Hoess A; Haberer T; Debus J
Acta Oncol; 2011 Aug; 50(6):784-90. PubMed ID: 21767175
[TBL] [Abstract][Full Text] [Related]
10. Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study "GUNMA0702".
Kawamura H; Kubo N; Sato H; Mizukami T; Katoh H; Ishikawa H; Ohno T; Matsui H; Ito K; Suzuki K; Nakano T;
BMC Cancer; 2020 Jan; 20(1):75. PubMed ID: 32000716
[TBL] [Abstract][Full Text] [Related]
11. Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: toxicity analysis.
Zilli T; Jorcano S; Peguret N; Caparrotti F; Hidalgo A; Khan HG; Vees H; Weber DC; Miralbell R
Acta Oncol; 2014 Jan; 53(1):96-102. PubMed ID: 24032443
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing bladder volume consistency during fractionated prostate radiation therapy.
Mullaney LM; O'Shea E; Dunne MT; Finn MA; Thirion PG; Cleary LA; McGarry M; O'Neill L; Armstrong JG
Pract Radiat Oncol; 2014; 4(5):e203-e212. PubMed ID: 25194106
[TBL] [Abstract][Full Text] [Related]
14. Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer.
Maruyama K; Tsuji H; Nomiya T; Katoh H; Ishikawa H; Kamada T; Wakatsuki M; Akakura K; Shimazaki J; Aoyama H; Tsujii H;
J Radiat Res; 2017 Mar; 58(2):260-266. PubMed ID: 28043947
[TBL] [Abstract][Full Text] [Related]
15. The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients.
Schaake W; Wiegman EM; de Groot M; van der Laan HP; van der Schans CP; van den Bergh AC; Langendijk JA
Radiother Oncol; 2014 Feb; 110(2):284-90. PubMed ID: 24411226
[TBL] [Abstract][Full Text] [Related]
16. Carbon-ion radiation therapy for prostate cancer.
Ishikawa H; Tsuji H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Tsujii H;
Int J Urol; 2012 Apr; 19(4):296-305. PubMed ID: 22320843
[TBL] [Abstract][Full Text] [Related]
17. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
18. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
19. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
20. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
